Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Telo Genomics Corp ( (TSE:TELO) ) has shared an announcement.
Telo Genomics Corp. has closed the first tranche of a non-brokered private placement of secured convertible debentures, raising gross proceeds of $840,000. The debentures carry 15% annual interest, mature on December 15, 2026, and are convertible into common shares at $0.05 per share, with investors also receiving warrants exercisable at $0.08 per share.
The company plans to use the funds to support lab trials and general working capital, incurring cash finder’s fees and issuing additional finder’s warrants as part of the financing. The offering remains subject to TSX Venture Exchange approval, and all securities issued in this first tranche are subject to a four-month-plus-one-day hold period under Canadian securities laws.
The most recent analyst rating on (TSE:TELO) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.
Spark’s Take on TSE:TELO Stock
According to Spark, TipRanks’ AI Analyst, TSE:TELO is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, persistent losses, and cash burn with negative equity), with technicals also indicating a broader downtrend. Corporate events provide some positive clinical/validation progress, but valuation remains constrained by ongoing losses and no dividend support.
To see Spark’s full report on TSE:TELO stock, click here.
More about Telo Genomics Corp
Telo Genomics Corp. is a biotech company specializing in diagnostic and prognostic tests based on chromosomal telomere analysis, with a focus on liquid biopsy applications in oncology and neurological diseases. Its proprietary telomere platform, supported by extensive clinical studies and publications, targets pathologists, clinicians, researchers and drug developers, with its lead product Telo-MM aimed at improving treatment decisions in multiple myeloma.
Average Trading Volume: 154,381
Technical Sentiment Signal: Sell
Current Market Cap: C$5.02M
See more insights into TELO stock on TipRanks’ Stock Analysis page.